UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

FORM 8-K

---



CURRENT REPORT



Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934



October 12, 2006 (October 12, 2006)

Date of Report (Date of earliest event reported)

---

AVAX TECHNOLOGIES, INC.

(Exact name of Registrant as specified in its charter)





|Delaware                                       | 000-29222                | 13-3575874                          
|---------------------------------------------- | ------------------------ | ------------------------------------
|(State or other jurisdiction
of incorporation) | (Commission File Number) | (IRS Employer
Identification Number)



2000 Hamilton Street

Suite 204

Philadelphia, PA  19130

(Address of principal executive offices, including zip code)



(215) 241-9760

(Registrants telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



| | o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
| | - | --------------------------------------------------------------------------------------



| | o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
| | - | ---------------------------------------------------------------------------------------



| | o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
| | - | -------------------------------------------------------------------------------------------------------



| | o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
| | - | -------------------------------------------------------------------------------------------------------





---

Item 8.01
        Other Events.




AVAX Technologies, Inc. (the
Company) has reached a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the
initiation of a registrable pivotal Phase III clinical trial for M-Vax, the Companys AC Vaccine technology for the treatment
of patients with Stage IV metastatic melanoma. The SPA is a written agreement between the Company and the FDA regarding the trial design,
surrogate endpoints to be used as a basis for accelerated approval of M-Vax and the statistical analysis plan necessary to support
regulatory approval of M-Vax. The SPA is further described in the Companys press release issued October 12, 2006, which is
filed as an exhibit to this Form 8-K and incorporated by reference.



Item 9.01
        Financial Statements and Exhibits.




(d)
        Exhibits.




The following exhibit is filed with this report:


99.1
        
        AVAX Technologies, Inc. Press Release issued October 12, 2006, announcing the Special Protocol Assessment Agreement with the FDA.






-1-

---



SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.





AVAX TECHNOLOGIES, INC.Date:  October 12, 2006.By:
        /s/   Richard P. RaineyName:
        Richard P. RaineyTitle:
        President




-2-

---